Dr Bristi Basu
Dr Bristi Basu is pleased to consider applications from prospective PhD students.
My research focus is in drug development and I translate preclinical findings on lead candidate agents into early phase clinical trials of novel therapeutic drugs as chief investigator, principal investigator and co-investigator in academic-led and industry-sponsored Phase I, II and III clinical trials, including first-in-human studies. My tumour site-specific focus is in hepato-pancreatico-biliary cancers, for which I am designing novel clinical trials based on preclinical research that has been performed at the Cambridge Pancreatic Cancer Centre. I am involved in projects of non-invasive imaging techniques that evaluate pharmacodynamic effects or show potential as early predictors for efficacy of anticancer drugs.
Symplectic Elements feed provided by Research Information, University of Cambridge
Hemant M Kocher, Bristi Basu, Fieke EM Froeling, Debashis Sarker, Sarah Slater, Dominic Carlin, Nandita M deSouza, Katja N De Paepe, Michelle R Goulart, Christine Hughes, Ahmet Imrali, Rhiannon Roberts, Maria Pawula, Richard Houghton, Cheryl Lawrence, Yathushan Yogeswaran, Kelly Mousa, Carike Coetzee, Peter Sasieni, Aaron Prendergast, David J Propper. Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Nature Comm 2020 Sep 24 10.1038/s41467-020-18636-w
Yap TA, Kristeleit R, Michalarea V, et al. Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers. Cancer Discov. 2020;CD-20-0163. doi:10.1158/2159-8290.CD-20-0163
Sarker D, Plummer R, Meyer T, et al. MTL-CEBPA, a small activating RNA therapeutic up-regulating C/EBP-α, in patients with advanced liver cancer: a first-in-human, multi-centre, open-label, phase I trial. Clin Cancer Res. 2020;clincanres.0414.2020. doi:10.1158/1078-0432.CCR-20-0414
Corrie PG, Qian W, Basu B, Valle JW, Falk S, Lwuji C, Wasan H, Palmer D, Scott-Brown M, Wadsley J, Arif S, Bridgewater J, Propper D, Gillmore R, Gopinathan A, Skells R, Bundi P, Brais R, Dalchau K, Bax L, Chhabra A, Machin A, Dayim A, McAdam K, Cummins S, Wall L, Ellis R, Anthoney A, Evans J, Ma YT, Isherwood C, Neesse A, Tuveson D, Jodrell DI. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. Br J Cancer. 2020 Apr 30. doi: 10.1038/s41416-020-0846-2. PubMed PMID: 32350413
Gallagher FA, Woitek R, McLean MA, Gill AB, Manzano Garcia R, Provenzano E, Riemer F, Kaggie J, Chhabra A, Ursprung S, Grist JT, Daniels CJ, Zaccagna F, Laurent MC, Locke M, Hilborne S, Frary A, Torheim T, Boursnell C, Schiller A,Patterson I, Slough R, Carmo B, Kane J, Biggs H, Harrison E, Deen SS, Patterson A, Lanz T, Kingsbury Z, Ross M, Basu B, Baird R, Lomas DJ, Sala E, Wason J, RuedaOM, Chin SF, Wilkinson IB, Graves MJ, Abraham JE, Gilbert FJ, Caldas C, Brindle KM. Imaging breast cancer using hyperpolarized carbon-13 MRI. Proc Natl Acad Sci U S A. 2020 Jan 28;117(4):2092-2098. doi: 10.1073/pnas.1913841117. Epub 2020 Jan 21. PubMed PMID: 31964840; PubMed Central PMCID: PMC6995024
Oza AM, Matulonis UA, Alvarez Secord A, Nemunaitis J, Roman LD, Blagden SP, Banerjee S, McGuire WP, Ghamande S, Birrer MJ, Fleming GF, Markham MJ, Hirte HW, Provencher DM, Basu B, Kristeleit R, Armstrong DK, Schwartz B, Braly P, Hall GD, Nephew KP, Jueliger S, Oganesian A, Naim S, Hao Y, Keer H, Azab M, Matei D. A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. Clin Cancer Res.2020 Mar 1;26(5):1009-1016. doi: 10.1158/1078-0432.CCR-19-1638. Epub 2019 Dec 12. PubMed PMID: 31831561; PubMed Central PMCID: PMC7056559
*Basu B, *Krebs MG, *Sundar R, Wilson RH, Spicer J, Jones R, Brada M, Talbot DC, Steele N, Ingles Garces AH, Brugger W, Harrington EA, Evans J, Hall E, Tovey H, de Oliveira FM, Carreira S, Swales K, Ruddle R, Raynaud FI, Purchase B, Dawes JC, Parmar M, Turner AJ, Tunariu N, Banerjee S, de Bono JS, Banerji U. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Ann Oncol. 2018 Sep 1;29(9):1918-1925. doi: 10.1093/annonc/mdy245 * joint 1st authors
N Cook, B Basu, D-M Smith, A Gopinathan, J Evans, W Steward, D Palmer, D Propper, B Venugopal, M Hategan, A Anthoney, L Hampson, M Nebozhyn, D Tuveson, H Farmer-Hall, H Turner, R McLeod, S Halford, D Jodrell “A Phase I trial of the ɣ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma” British Journal of Cancer 2018 Feb 13. doi: 10.1038/bjc.2017.495
FM Walter, K Mills, S Mendonca, G Abel, B Basu, N Carroll, S Ballard, J Lancaster, W Hamilton, GP Rubin, JD Emery. “Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer: a prospective cohort study” The Lancet Gastroenterology & Hepatology 2016 1: 298–306 http://dx.doi.org/10.1016/S2468-1253(16)30079-6
B Basu*, E Dean*, M Puglisi, A Greystoke, M Ong, W Burke, M Cavallin, G Bigley, C Womack, E A Harrington, S Green, E Oelmann, J S de Bono, M Ranson, U Banerji. “First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor, AZD2014” Clinical Cancer Research *Joint first authors 2015 Aug 1;21(15):3412-9
B Basu, P Correa-Sampaio, H Mohammed, M Fogarasi, W English, N Watkins, P Corrie, W Ouwehand, G Murphy. “Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain” International Journal of Biochemistry and Cell Biology 2012 Feb; 44(2): 393-403.